Abstract: Provided are pyrimidine aromatic ring compounds. Specifically provided is a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.

Abstract: Embodiments of the present disclosure are directed to a gate driving circuit and a display panel. The gate driving circuit includes a plurality of cascaded gate driving units. Each of the gate driving unit includes a pull-up control module, a pull-up module electrically connected to the pull-up control module through a first node and electrically connected to a scan line, a pull-down module electrically connected to the scan line, and a first pull-down maintaining module. The first pull-down maintaining module includes a first auxiliary module and a first pull-down maintaining transistor having a drain connected to the first node. The first auxiliary module, electrically connected to a gate of the first pull-down maintaining transistor, and configured to control an on/off state of the first pull-down maintaining transistor.

Abstract: The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.

Abstract: The present invention discloses a right-angle turning method for small-diameter TBM exploration adit excavation and belongs to the field of geological exploration of water conservancy and hydropower projects.

Abstract: The present disclosure relates to compounds of Formula (I), and the pharmaceutically A—(CH2)m—X—Y—Z—B1??I, acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer).

Abstract: A four-notch flexible wearable ultra-wideband antenna fed by coplanar waveguide, includes a flexible base. A ground plane, a radiation patch and a feeder are arranged on the flexible base. There are several resonant tanks on the feeder and the radiation patch. The flexible base is made of insulating flexible material, and the feeder, the radiation patch and the ground plane are made of conductive flexible material. The four-notch flexible wearable ultra-wideband antenna fed by coplanar waveguide of the present application can be prepared by layer-by-layer assembly technology, spray printing or printed circuit board technology, and has the advantages of miniaturization and low profile, compact structure, convenient production, good conformality, wearable and other advantages.

Abstract: The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.

Abstract: For the problem of difficult roof anchor withdrawal at the end of a working face, a static crushing directional anchor withdrawal method at the end of a large-mining-height working face is provided. The method includes the following steps: designing key parameters of boreholes for static crushing, including a borehole position, a spacing between boreholes, a borehole depth, and a borehole diameter at the end of a working face; then determining parameters of a static crushing agent grouting technology device for the construction of a static crushing process; and carrying out an anchor withdrawal operation at the end.

Abstract: A class of lactam-modified polypeptide compounds and the use thereof in the preparation of a drug for treating related diseases.

Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

Abstract: Described herein are compounds of Formula I and conjugates of Formula I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

Abstract: A vilazodone pharmaceutical composition, a preparation method therefor and use thereof are provided. The vilazodone pharmaceutical composition are in vilazodone solid particles. The vilazodone solid particles have a Dv(10) particle size not greater than 20 microns, a Dv(50) particle size not greater than 50 microns and a Dv(90) particle size not greater than 100 microns. The vilazodone pharmaceutical composition has significant advantages such as long-acting sustained release, reducing the frequency of administration, and improving patient compliance.

Abstract: A display panel and a display device are provided. In the display panel, a plurality of scan lines are disposed in a display area and extended to the non-display area. A GOA circuit and a plurality of signal transmission lines are disposed in the non-display area. The GOA circuit includes multi-level cascaded GOA units. Each of GOA units is electrically connected with at least one scan line through corresponding signal transmission line. A repair line is disposed between the GOA circuit and the display area and extended along the first direction. The repair line crosses the scan line or the signal transmission line and is arranged in different layers.

Abstract: The present disclosure provides a device for preventing frost heaving and thawing settlement. The device includes a positioning cylinder, an upper cover, an anti-thawing settlement rod configured to prevent the thawing settlement, and an anti-frost heaving rod configured to prevent the frost heaving. The upper cover is sealingly assembled on a top of the positioning cylinder. A bottom of the positioning cylinder is provided with the anti-frost heaving rod. An upper portion of the positioning cylinder is provided with the anti-thawing settlement rod. The anti-frost heaving rod is provided upwards, and a bottom of the anti-frost heaving rod is rotatably provided on a mounting base of the anti-frost heaving rod through a first connecting screw rod. The anti-thawing settlement rod is provided downwards, and a top of the anti-thawing settlement rod is rotatably provided on a mounting base of the anti-thawing settlement rod through a second connecting screw rod.

Abstract: An in-situ vapor injection thermal desorption device includes a sectional combined input head, several intermediate connectors and a bottom protector connected in series from top to bottom. The in-situ vapor injection thermal desorption device further includes several water-vapor coupling injection activation chips, selectively disposed below any of the intermediate connectors; the sectional combined input head is provided with a high-pressure-gas inlet, several pairs of heat-transfer-oil inlets and heat-transfer-oil outlets, and several pairs of hot-water inlets and hot-water outlets; the water-vapor coupling injection activation chip is provided with several gas-liquid spraying holes.

Abstract: A pharmaceutical composition containing cariprazine, a preparation method and an application thereof are provided. The pharmaceutical composition contains cariprazine pamoate solid particles. A particle size of the cariprazine solid particles has a Dv(10) less than or equal to 30 microns, a Dv(50) less than or equal to 50 microns, and a Dv(90) less than or equal to 100 microns. When being used, the pharmaceutical composition containing cariprazine is an aqueous suspension and, the concentration of the free base of cariprazine is moderate. A long-term effect can be achieved upon injection of a certain administration volume of the pharmaceutical composition, thereby reducing the frequency of medication while increasing patient medication compliance. Furthermore, the pharmaceutical composition has a high bioavailability and has promising marketing prospects.

Abstract: Provided is a method for adjusting a target object, an electronic device, and a storage medium, relating to a field of computer technology, and in particular, to fields of intelligent transportation, automatic driving, computer vision, and the like. The method includes: acquiring a first bounding box corresponding to the target object and a second bounding box corresponding to a support of the target object; obtaining an association relationship for adjustment of the target object, according to a spatial position where the first and second bounding boxes are located; and moving, according to the association relationship, the target object towards the support, to obtain a third bounding box corresponding to the adjusted target object, where the third bounding box and the second bounding box appear to fit each other.

Abstract: A method for extracting a dam emergency event based on a dual attention mechanism is provided. The method includes: performing data preprocessing, building a dependency graph, building a dual attention network, and filling a document-level argument. The performing data preprocessing includes labeling a dam emergency corpus and encoding sentences. Building a dependency graph includes assisting a model to mine a syntactic relation based on a dependency. Building a dual attention network includes weighing and fusing an attention network based on a graph transformer network (GTN) and capturing key semantic information in the sentence. Filling a document-level argument includes filling a document-level argument by detecting a key sentence and ordering a semantic similarity. The method introduces a dependency and overcomes the long-range dependency problem based on the dual attention mechanism, thus achieving high identification accuracy and reducing a lot of labor costs.

Abstract: A pharmaceutically acceptable salt of cariprazine, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof are provided. The pharmaceutically acceptable salt of cariprazine is a salt formed from the free base of cariprazine and an organic acid having six or more carbon atoms, and has relatively good solubility and stability.